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It is now widely accepted that compensatory mechanisms are involved during the early phase of Parkinson’s disease (PD) to delay the
expression of motor symptoms. However, the neurochemical mechanisms underlying this presymptomatic period are still unclear.
Here, we measured in vivo longitudinal changes of both the dopaminergic and serotonergic systems in seven asymptomatic 1-methyl-4-
phenyl-1,2,3,6-tetrahydropyridine (MPTP)-intoxicated monkeys (when motor symptoms are less apparent) using PET. We used the
progressively MPTP-intoxicated monkey model that expresses recovery from motor symptoms to study the changes in dopamine syn-
thesis ([18F]DOPA), dopamine D2 /D3 receptors ([
11C]raclopride), and serotonin transporter 11C-N,N-dimethyl-2-(-2-amino-4-
cyanophenylthio) benzylamine ([11C]DASB) and serotonin 1A receptor ([18F]MPPF) levels between four different states (baseline, early
symptomatic, full symptomatic and recovered). During the early symptomatic state, we observed increases of [18F]DOPA uptake in the
anterior putamen, [11C]raclopride binding in the posterior striatum, and 2-methoxyphenyl-(N-2-pyridinyl)-p-[18F]fluoro-
benzamidoethylpiperazine [18F]MPPF uptake in the orbitofrontal cortex and dorsal ACC. After recovery from motor symptoms, the
results mainly showed decreased [11C]raclopride binding in the anterior striatum and limbic ACC. In addition, our findings supported the
importance of pallidal dopaminergic neurotransmission in both the early compensatory mechanisms and the functional recovery mech-
anisms, with reduced aromatic L-amino acid decarboxylase (AAAD) activity closely related to the appearance or perseveration of motor
symptoms. In parallel, this study provides preliminary evidence of the role of the serotonergic system in compensatory mechanisms.
Nonetheless, future studies are needed to determine whether there are changes in SERT availability in the early symptomatic state and if
[18F]MPPF PET imaging might be a promising biomarker of early degenerative changes in PD.
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Significance Statement
The present research provides evidence of the potential of combining a multitracer PET imaging technique and a longitudinal
protocol applied on a progressively 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-intoxicated monkey model to further elucidate
the nature of the compensatory mechanisms involved in the preclinical period of Parkinson’s disease (PD). In particular, by
investigating the dopaminergic and serotonergic changes both presynaptically and postsynaptically at four different motor states
(baseline, early symptomatic, full symptomatic, and recovered), this study has allowed us to identify putative biomarkers for
future therapeutic interventions to prevent and/or delay disease expression. For example, our findings suggest that the external
pallidum could be a new target for cell-based therapies to reduce PD symptoms.
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Introduction
Parkinson’s disease (PD) is a neurodegenerative disorder clini-
cally characterized by the progressive emergence of motor symp-
toms. However, those impairments are observed only when the
striatal level of DA has decreased by 60 – 80% (Bernheimer et al.,
1973). During the early phase of the disease, parkinsonian pa-
tients do not show motor symptoms despite progressive but
strong dopaminergic depletion. This suggests the existence of
impressive compensatory mechanisms in this presymptomatic
period to counterbalance the degenerative process (Zigmond,
1997). Human PET imaging studies have shown that, early in the
disease, the activity of the enzyme aromatic L-amino acid decar-
boxylase (AAAD) is increased in the preserved striatal dopami-
nergic terminals (Lee et al., 2000; Ribeiro et al., 2002), as well as in
extrastriatal structures such as the pallidum (Whone et al., 2003)
and the cingulate cortex (Rakshi et al., 1999). In addition, in-
creased dopamine (DA) release (Snyder et al., 1990; Schneider et
al., 1994) or turnover by the remaining axons (Agid et al., 1973;
Altar et al., 1987) and increased numbers or sensitivity of the DA
receptors (Zigmond et al., 1984; Bezard and Gross, 1998) have
been observed in PD animal models. Altogether, these findings
have emphasized the role of dopaminergic compensatory mech-
anisms. Nonetheless, nondopaminergic systems could also play a
role in compensation, such as the GABAergic (Schroeder and
Schneider, 2002), glutamatergic (Bezard et al., 1998), and seroto-
nergic systems (Gaspar et al., 1993; Mounayar et al., 2007; Boulet
et al., 2008). The precise neurochemical mechanisms involved
during the early phase of the disease are still unclear.
To gain further understanding of these compensatory
mechanisms, we previously used a progressive approach of
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-intoxi-
cated monkey model of PD (Mounayar et al., 2007; Boulet et al.,
2008; Neumane et al., 2012). With this method, monkeys devel-
oped all the motor symptoms and then fully recovered after the
final MPTP injection despite a large DA denervation, suggesting
that compensatory mechanisms could be involved in the recovery
process. Overall, our studies supported the notion that residual
striatal DA played a role in compensation in PD, revealed the
importance of extrastriatal structures such as the external palli-
dum, and highlighted the possible involvement of serotonin
(5-HT). However, the conclusions were limited because the ob-
served changes were restricted to the subcortical presynaptic level
and there is no evidence yet that the recovery process involves the
same mechanisms as those involved during the presymptoma-
tic state of PD when the level of dopaminergic lesion is less
pronounced.
Accordingly, in the present study, we combined a multitracer
PET imaging method and a longitudinal protocol using this pro-
gressively MPTP-intoxicated monkey model of PD to investigate
the in vivo changes in the DA and 5-HT systems both at the
presynaptic and the postsynaptic levels. Because functional com-
pensatory mechanisms might differ depending on the extent of
dopaminergic denervation, we successively observed the changes
between four different motor states, starting from baseline, fol-
lowed by an early symptomatic and then a full symptomatic par-
kinsonian state, and proceeding to the recovered state. We used
both the [18F]DOPA (thought to reflect AAAD activity) and
[11C]raclopride (a selective dopamine D2/D3 receptors antago-
nist) radiotracers to identify regions with dopaminergic dysfunc-
tions, as described previously in human studies (for review, see
Brooks and Pavese, 2011). Abnormalities in both serotonin
transporter (SERT) availability (Politis et al., 2010a, 2010b) and
5-HT1A receptors (Ballanger et al., 2012) have been associated
with depression in PD patients, a nonmotor symptom that
often appears years before motor disturbances. Therefore,
follow-up of the serotonergic system has been addressed using
the 11C-N,N-dimethyl-2-(-2-amino-4-cyanophenylthio) ben-
zylamine ([11C]DASB) (a specific marker of SERT availability)
and 2-methoxyphenyl-(N-2-pyridinyl)-p-[18F]fluoro-benza-
midoethylpiperazine ([18F]MPPF) (a selective 5-HT1A receptor
antagonist) radiotracers to identify regions with respectively pre-
synaptic and/or postsynaptic 5-HT dysfunctions. We hypothe-
sized that there would be an early increase in presynaptic DA
activities in structures less affected by MPTP toxicity, followed
by a profound decrease during the full parkinsonian motor
state, whereas the recovery process should involve modifica-
tions in DA receptors and 5-HT compensatory activities.
Materials and Methods
Animals. Seven male cynomolgus monkeys (Macaca fascicularis, MF)
between 3 and 5 years old (young adults) and weighing 4 – 6 kg were
provided by Tamarinier Ltee, Mauritius Island and used in this study.
These monkeys were cared for and treated in strict accordance with
National Institutes of Health guidelines (1996) and with the European
Community Council Directive of 2010 (2010/63/UE) and the recom-
mendations of the French National Committee (2013/11).
MPTP treatment and experimental schedule. The timeline of the exper-
imental design is shown in Figure 1A. After collection of baseline PET
imaging data, the animals were given intramuscular MPTP injections
(0.3– 0.6 mg/kg body weight; Sigma-Aldrich) performed under light an-
esthesia (ketamine 0.5 mg/kg, atropine 0.05 mg/kg) at intervals of 4 –5 d
until the emergence of most of the motor parkinsonian symptoms. The
total MPTP dose given to each monkey varied between 1.2 and 2.2 mg/kg.
Once MPTP injections were stopped, almost all the animals (5/7) totally
recovered spontaneously from their motor symptoms (Fig. 1C).
Throughout the study, the severity of parkinsonism was evaluated
using the rating scale proposed by Schneider and Kovelowski (1990). We
have already described the effects of MPTP evaluated using this rating
scale in previous studies (Pessiglione et al., 2004; Mounayar et al., 2007;
Boulet et al., 2008). Briefly, this scale includes 12 items rated between 0
and 2 or 3, with a total score of 29. It takes into account classical motor
symptoms (bradykinesia, rigidity, tremor, freezing, posture and arm
posture), but also spontaneous activities (arm movements, spontaneous
eye movements, and home cage activity) and other activities (vocaliza-
tion, triggered eye movements, and feeding). For each monkey, the
evolution of these measurements was evaluated daily by one or two ex-
perimenters accustomed to handling the animals. Moreover, all of the
evaluation sessions were recorded to allow additional evaluations by an
experimenter blinded to the state of the animal. During these additional
evaluations, the intensity of some items was evaluated by quantitative
measurement of specific events (counting of eye and arm movements
and home cage activity), which were statistically compared with mea-
surements made during baseline periods before MPTP treatment. For
these measurements, a score of 1, 2, or 3 indicated a statistical reduction
of 50%, a statistical reduction of 90%, or a complete absence of
movement, respectively. Some symptoms were evaluated specifically in
either the chair (rigidity, spontaneous and triggered eye movements, and
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arm movements during tasks) or the cage (home cage activity), whereas
the other symptoms were evaluated in both the chair and the cage (bra-
dykinesia/akinesia, posture). The home cage activity was evaluated using
closed circuit television and an activity digitalization system (Vigie Pri-
mates; for details, see Mounayar et al., 2007).
PET scans were acquired longitudinally at four different times: (1) in
the baseline state, (2) in the early symptomatic state (4 –5 d after the
second MPTP injection), (3) in the full symptomatic state (between 4 and
14 d after the last MPTP injection during the peak of motor symptoms),
and (4) in the recovered state (at least 1 week after the parkinsonian score
returned to 0). However, it was not possible to undertake PET with all of
the radiotracers in all of the animals, which therefore explains the differ-
ent number of animals within each state (Fig. 1A). The mean time (days)
between last MPTP dose and PET scans was (mean  SD) 11  3 for
the early symptomatic state, 9  5 for the full symptomatic state, and
59  22 for the recovered state (Fig. 1B). On the day of each PET scan, the
monkeys were pretreated with atropine (0.05 mg/kg) and 15 min later were
anesthetized by an intramuscular dose of zoletil (15 mg/kg). The monkeys
were then transported to the Imaging Centre (CERMEP, Lyon, France),
where they were placed in a PET-compatible stereotaxic apparatus. Anesthe-
sia was maintained during the scan and a lactated Ringer’s solution was
infused continuously through a saphenous vein catheter. The respiratory
frequency, pO2, and heart rate were monitored throughout the experiment.
PET data acquisition. All PET scans were performed in 3D mode using
a Siemens CTI HR  tomograph, with an axial field of view of 15.2 cm,
yielding 63 planes and a nominal in-plane resolution of 4.1 mm FWHM
according to the NEMA protocol (Brix et al., 1997). PET measurements
were performed with four radiotracers: [18F]DOPA, [11C]raclopride,
[11C]DASB, and [18F]MPPF. For each experimental state, the mean time
(days) between PET scans was (mean  SD) 20  13 for the baseline
state, 5  2 for the early symptomatic state, 7  4 for the full symptom-
atic state, and 12  6 for the recovered state. It should be noted that the
[11C]raclopride and [18F]MPPF PET scans were always acquired in 1 d,
with the [11C]raclopride collected first due to the short half-life of
carbon-11. Except for those two ligands, the order of PET scans was
randomized for each monkey and each state to avoid, as far as possible, the
neurochemical effects of anesthesia. Although we cannot exclude that re-
peated anesthesia may have had an effect on our PET results, it is worth
mentioning that treatment with zoletil does not affect the binding of dopa-
minergic and serotonergic transporters’ radioligands (Elfving et al., 2003).
Before the tracer injection, a transmission scan (68 Ge rotating rod
sources; 10 min) was acquired to correct for tissular 511 keV gamma atten-
uation. Dynamic acquisition started with the intravenous injection of the
radiotracer and lasted 100 min for [18F]DOPA, 90 min for [11C]DASB, 70
min for [18F]MPPF, and 60 min for [11C]raclopride PET scans. Synthesis of
radioligands was performed in the cyclotron unit of the CERMEP. The mean
doses (SD) of injected [18F]DOPA, [11C]raclopride, [11C]DASB, and
[18F]MPPF were 139  24, 143.9  29.6, 156.9  20, and 136.2  28.1 MBq,
respectively. The 3D emission data were reconstructed with attenuation and
scatter correction by a 3D filtered back projection (Hamming filter; cutoff
frequency, 0.5 cycles/pixel) algorithm and a zoom factor of three. Recon-
structed volumes were 128  128 matrices of 0.32  0.32 mm2 pixels in 63
2.42 mm spaced planes.
PET data preprocessing. To obtain parametric images, the PET studies
were analyzed by suitable tracer kinetic modeling. The parameters com-
puted were the uptake rate (Ki, 10
3 min 1) for [18F]DOPA and the
BPND of [
11C]raclopride, [11C]DASB, and [18F]MPPF. The [18F]DOPA
Ki was calculated using frames recording for between 30 and 90 min for
Figure 1. Study design and schedule of PET scan acquisitions. A, Timeline of the experimental design with the number (n) of animals in each state and for each radioligand. B, Mean time (days)
SD between last MPTP injection and PET acquisition for each radioligand. C, Evolution of parkinsonian score during MPTP intoxication and recovery. Data represent the evolution of appearance and
disappearance of motor symptoms during and after MPTP intoxication. Timelines are aligned such that day 0 corresponds to the day on which the maximal parkinsonian score was obtained from an
individual animal. The rectangle represents PET scan acquisition. D, Positive correlation between maximal parkinsonian score and the time needed for each animal to recover spontaneously from
their motor symptoms once MPTP injections were stopped (n  7).
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the linearization and the Patlak graphical analysis, considering the cere-
bellum as the reference area. Parametric images of BPND were obtained
using a simplified reference tissue model (Gunn et al., 1997) with the
cerebellum as the reference. Using Statistical Parametric Mapping
(SPM8, Wellcome Trust Centre for NeuroImaging, University College
London) in MATLAB (version 8.1, R2013a; The MathWorks), the para-
metric images were transformed into a common space using the brain
Macaca fascicularis MRI template (Ballanger et al., 2013) available from
http://www.cermep.fr (section download/atlas). Finally, a Gaussian-
smoothing kernel of 6 mm was applied to the normalized parametric
images to localize significant changes at the voxel level.
ROI-based analysis. Tissue time–activity concentration curves were
extracted using our maximum probability atlas (Ballanger et al., 2013)
for eight ROIs within the BG (namely the anterior and posterior parts of
the putamen, the caudate nucleus, the ventral striatum, and the external
and internal segments of the pallidum), as well as 11 other ROIs within
the thalamus; the raphe nucleus; the dorsal and ventral parts of the
ACC; the dorsolateral, medial, orbital, and ventral parts of the frontal
cortex; the amygdala; the hippocampus; and the insula considering re-
gional distribution of DA and 5-HT.
Histological procedures for dopaminergic cell loss. At the end of the experi-
ments, the monkeys received a lethal overdose of anesthetic drug (pentobar-
bital) and were then transcardially perfused with saline, followed by 5 L of
4% paraformaldehyde fixative solution. The brains were removed from the
skull, immersed in PBS with 20% sucrose for 48 h, frozen, and cut into
50-m-thick frontal sections perpendicular to the intercommissural plane,
which were stored for immunohistochemical procedures (see details in Jan
et al., 2000). Dopaminergic innervation of the SN cell loss was studied by
immunocytochemical localization of TH (see details in Mounayar et al.,
2007). In the SNc, TH-positive cells were counted in nine regularly spaced
sections covering the anteroposterior extent of the structure using an image
analysis system (Mercator; ExploraNova). The sections were matched ana-
tomically in each of the animals and the total number of TH-positive cells
was estimated after correction using the Abercrombie method. The percent-
age of neuronal loss in the SNc was evaluated by comparison with baseline
values from four intact monkeys (Table 1).
Statistical analyses. Statistical differences in ROIs Ki and BPND among
the four different states were assessed using two-way repeated-measures
ANOVA, followed by the Holm post hoc test (see Table 2 for details). It
should be noted that the [11C]DASB PET scan of MF11 collected in the
recovered state was excluded for technical reasons. Nonlinear multivar-
iate regressions were used to analyze dependences between the behav-
ioral markers (motor scores and recovery time), the histological markers
(SN cell loss), and the different binding parameters. For all of the statis-
tical analyses performed using STATA 10.0/SE (StataCorpLP), a proba-
bility level of 	5% ( p 	 0.05) was considered to be significant.
In parallel, for an exploratory search involving the entire cortex, we
also performed on the normalized parametric images voxel-by-voxel
analyses using SPM8 software. Due to the small sample size, statistical
maps were thresholded at a level of p 	 0.001 uncorrected with an extent
threshold of at least 80 contiguous voxels. For visualization, voxelwise
levels of significance (t-maps) were projected onto the MF MRI template
(Ballanger et al., 2013).
Results
MPTP intoxication, evolution of motor score during
intoxication, and recovery
The monkeys received 3–5 injections of MPTP for a cumulative
dose of 1.2 to 2.2 mg/kg (mean 1.6 mg/kg). Four monkeys (MF6,
MF7, MF10, and MF11) were scanned in an early symptomatic
state after two MPTP injections (parkinsonian scores of 8, 6, 5,
and 1, respectively, at the time of the [18F]DOPA scan and of 9, 3,
5, and 1, respectively, at the time of the [11C]raclopride and
[18F]MPPF scans; Fig. 1C). Among those animals, MF6 already
presented overt mild motor symptoms (including bradykinesia,
rigidity, freezing, and parkinsonian posture) and a slight reduc-
tion in the analysis of home cage activity and spontaneous eye
movements associated with a mild parkinsonian posture were
reported in the other animals. After full MPTP intoxication, all
animals (7/7) developed motor symptoms and exhibited recov-
ery after stopping treatment (Fig. 1C). Recovery was complete for
most of the monkeys (5/7), whereas two monkeys (MF3 and
MF10) presented only a partial recovery with mild motor symp-
toms (parkinsonian scores of 9 and 8, respectively, at the end; Fig.
1C). Of particular interest, in both monkeys, bradykinesia, par-
kinsonian posture, and a reduction in home cage activity were
still observed during the recovery period. Interestingly, the max-
imal parkinsonian score obtained for those 2 monkeys (22.5 
0.7) was greater than the maximal score observed in monkeys
with total recovery (13.4  4.5). Recovery after the maximal
effect and cessation of MPTP injections was gradual over 4 – 8
weeks (mean 38.8  10.9 d to maximal recovery; Fig. 1C). No
correlation was found between the motor score and the cumula-
tive dose of MPTP received by each animal (r  0.63, p  0.13,
n  7). A positive correlation was found between the motor score
and the recovery time (r  0.85, p  0.015, n  7), indicating
that, the greater the maximal effect, the longer the time to recov-
ery (Fig. 1D). Finally, the maximal motor score was positively
correlated with the total dopaminergic cell death in the SN (r 
0.87, p  0.023, n  6). Specifically, cell death in A9 and A10 were
significantly correlated with motor scores (r  0.85, p  0.032
and r  0.84, p  0.036, respectively, n  6). It is worth noting
that cell death in A8 was not correlated with motor scores (r 
0.19, p  0.72, n  6). No significant correlation was reported
between cell death and recovery time.
PET imaging at baseline
As expected, the regional distribution of radioactivity was in good
agreement with that known from in vivo studies in humans for
each radiotracer, with the highest uptake in the striatum for both
the [18F]DOPA and [11C]raclopride radiotracers (Ito et al., 1999;
Nagano et al., 2000), in the raphe and the thalamus for the
[11C]DASB (Houle et al., 2000; Wilson et al., 2002), and in vari-
ous components of the limbic system (such as the dorsal ACC, the
insula, and the hippocampus) for [18F]MPPF ligand (Aznavour
and Zimmer, 2007; Fig. 2A, Table 2).
Regression analyses
Interestingly, both [11C]raclopride BPND and [
11C]DASB BPND
collected at baseline were inversely related to the maximal par-
kinsonian score (corresponding to the full symptomatic motor
state) in multiple regions. In particular, negative correlations
were reported within both the left GPe and GPi (r  0.99, p 
0.002 and r  0.93, p  0.02 respectively, Fig. 2B, n  5) for the
[11C]raclopride BPND and in the amygdala (r  0.88, p 
0.049), hippocampus (r  0.88, p  0.047), PCC (r  0.98,
Table 1. Dopaminergic cell loss
Monkey
Dopaminergic cell loss (%)
TotalA8 A9 A10
MF3 74 86.4 73.2 78
MF4 71.6 75.4 65.1 70.8
MF5 72 80.8 68.1 73.8
MF6 58.1 78.2 50.4 62.5
MF7 71 68.3 61 66.9
MF10 Data not available
MF11 81.4 67.8 58 69.5
Mean 71.4 76.2 62.6 70.3
SD 7.5 7.2 8 5.4
Data represent the percentage of neuronal loss in the substantia nigra collected for each monkey (MF) at the end of
the study (with the exception of MF10).
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p  0.004), left insula (r  0.90, p  0.037), and right dorsal
ACC (r  0.91, p  0.032), as well as the GPe and GPi (r 
0.92, p  0.025 and r  0.93, p  0.02, respectively, Fig. 2B),
the posterior striatum (r  0.92, p  0.027 for the caudate, r 
0.98, p  0.005 for the putamen), and the posterior ventral
striatum (r  0.92, p  0.026) for the [11C]DASB BPND (n 
5).Moreover, we also found a negative correlation between the
total time to recovery and the [11C]DASB BPND collected at base-
line in the amygdala (r  0.94, p  0.017), hippocampus (r 
0.93, p  0.02), and the GPe and GPi (r  0.94, p  0.019 and
r  0.96, p  0.009, respectively) and the posterior parts of the
putamen and the ventral striatum (r  0.93, p  0.023 and r 
0.97, p  0.005, respectively, n  5). Finally, cell death in A9
was negatively correlated with [18F]DOPA uptake collected at
baseline within the GPe and the putamen posterior (r  0.90,
p  0.01 and r  0.85, p  0.03 respectively, n  6), whereas
cell death in A8 was negatively correlated with [11C]raclopride
binding collected at baseline within the anterior caudate
(r  0.92, p  0.025, n  5) and the putamen in its anterior (r 
0.97, p  0.005, n  5) and posterior parts (r  0.92, p 
0.026, n  5). In parallel, there was also a negative relationship
between the percentage of cell death in A8 and the level of
[11C]DASB binding collected at baseline within the anterior pu-
tamen (r  0.99, p  0.01, n  4). It is worth noting that cell
death in A10 was negatively correlated with 11C]raclopride binding
collected at baseline in both the GPe (r  0.96, p  0.008, n  5)
and the putamen posterior ventral (r  0.96, p  0.01, n  5),
whereas the percentage of total dopaminergic cell death within the
SN was inversely related to the level of [11C]DASB binding collected
at baseline within the GPi (r  0.96, p  0.04, n  4).
Changes in the early symptomatic state
Compared with baseline, ROI-based analyses only revealed a
trend for an increase in [18F]MPPF BPNDin the early symptom-
atic state within the anterior caudate (F(1,15)  8.67, p  0.06) and
the orbitofrontal cortex (F(1,15)  8.52; p  0.053; Table 2). In
parallel, SPM analyses revealed a cluster (k  563 voxels) of in-
creased Ki with a peak of activity in the left anterior putamen (T 
7.98; Fig. 3B); two clusters of increased [11C]raclopride BPND in
the right and left parts of the posterior putamen (T  9.11, k 
447 voxels and T  8.42, k  102 voxels respectively, Fig. 4B); and
three clusters of increased [18F]MPPF BPND in the right orbito-
frontal cortex (k  139 voxels, T  58.28), right dorsal ACC (k 
660 voxels, T  55.08), and right orbitofrontal cortex extending
to the anterior caudate (k  119 voxels, T  47.8; Fig. 5B). Fi-
nally, regression analysis showed a negative relationship between
[18F]DOPA uptake and motor status (both collected in the early
symptomatic state) within the right GPe (r  0.97, p  0.047,
n  4; Fig. 3D).
Changes in the full symptomatic state
Compared with baseline, ROI assessment of [18F]DOPA uptake
showed a significant decrease in the putamen (in its anterior
(F(1,15)  9.22; p  0.049) and posterior (F(1,15)  12.85; p 
0.011) parts) and the caudate nucleus (in its anterior (F(1,15) 
9.35; p  0.048) and posterior (F(1,15)  16.21; p  0.0066) parts;
Fig. 3A). Interestingly, the Ki values collected during the full
symptomatic state were also significantly reduced compared with
the early symptomatic state in the posterior striatum (F(1,15) 
9.88; p  0.02 and F(1,15)  8.87; p  0.037 for the putamen and
the caudate, respectively). The SPM analysis was in good agree-
ment with these latter findings by revealing four clusters of de-
creased Ki values in the full symptomatic compared with the early
symptomatic state within the left and right posterior putamen
(k  1282, T  6.23 and k  527, T  4.96), as well as the left and
right caudate posterior (k  490, T  5.42 and k  104, T  4.83,
respectively). In the pallidum, the SPM analysis (full symptom-
atic state vs baseline) revealed a significant decrease of Ki values
within the bilateral GPe (k  547 voxels and T  8.63 for the left
side and k  439 voxels, T  6.22 for the right side, data not
shown). In parallel, ROI analysis of [11C]raclopride BPND
showed a trend for an increase in the anterior caudate nucleus
compared with baseline (F(1,12)  8.62; p  0.06; Fig. 4A, Table
2), whereas the SPM analysis revealed a significant increase of
[11C]raclopride BPND in the posterior putamen [T  5.3 for the
cluster (k  112) in the left side and T  5.12 for the cluster (k 
98) in the right side; Figure 4C]. Assessment of 5-HT innervation
using PET imaging of the SERT with [11C]DASB revealed a
significant increase (compared with baseline) in the posterior
putamen (F(1,7)  22.34; p  0.0064) and the pallidum in its
external (F(1,7)  13.17; p  0.025) and internal (F(1,7)  10.8;
p  0.04) segments (Fig. 6 A, B, Table 2). At the postsynaptic
level, SPM analysis revealed a cluster of increased [18F]MPPF
BPND in the right DLPFC (k  127 voxels, T  6.85, data not
shown).
Table 2. Evolution of 
18FDOPA uptake and 
11CRaclopride, 
11CDASB, and 
18FMPPF bindings among the different states and the different regions of interest
Region Part

18FDopa Ki unit  10
3 min 1 
11CRaclopride BPND 

11CDASB BPND 

18FMPPF BPND
Baseline
(n  7)
Early
(n  4)
Symptomatic
(n  7)
Recovered
(n  7)
Baseline
(n  5)
Early
(n  4)
Symptomatic
(n  6)
Recovered
(n  7)
Baseline
(n  5)
Symptomatic
(n  5)
Recovered
(n  4)
Baseline
(n  7)
Early
(n  4)
Symptomatic
(n  7)
Recovered
(n  7)
Putamen Anterior 5  2.2 5.3  2.2 2.2  2 † 2  0.8 ‡ 3.7  0.8 3.8  0.4 4.2  0.6 3.3  0.7 †‡ 1.17  0.2 1.3  0.3 1.19  0.2 0.74  0.2 0.89  0.2 0.84  0.2 0.79  0.1
Posterior 5.2  2.3 6.2  3.6 1.9  2.3 †/*† 1.3  0.7 ‡/*‡ 4  0.3 4.6  0.2 4.9  0.4 4.1  0.8 1.09  0.2 1.24  0.2 † 1.13  0.2 †‡0.058 0.62  0.2 0.72  0.2 0.7  0.1 0.65  0.2
Caudate Anterior 4.3  2.3 3.8  1.9 1.8  1.7 † 1.9  0.8‡0.053 3.6  0.5 3.7  0.3 4  0.5 †0.06 3  1.1 †‡ 0.88  0.2 1.02  0.3 0.92  0.2 0.56  0.2 0.73  0.2*0.06 0.66  0.2 0.67  0.1
Posterior 3.8  2.2 3.8  2.8 1  1.1 †/*† 1.1  0.6 ‡/*‡ 3.1  0.2 3.5  0.5 3.6  0.7 2.8  1.1 0.9  0.2 1.04  0.3 0.94  0.2 0.38  0.1 0.44  0.1 0.42  0.1 0.45  0.2
Ventral
striatum
Anterior 3.4  1.6 4.1  1.4 2.8  1.5 3.2  0.7 2  0.6 2  0.4 2  0.4 1.8  0.3 1.11  0.3 1.18  0.5 1.15  0.3 0.64  0.2 0.81  0.3 0.72  0.2 0.69  0.2
Posterior 2.2  1 2.7  1.8 1.1  0.9 1.2  0.5 2  0.3 2.2  0.2 2.2  0.3 2.5  1.4 1.05  0.2 1.15  0.4 1.06  0.3 0.71  0.1 0.70  0.1 0.75  0.1 0.69  0.2
Pallidum External 4.4  2.7 6  4.2 2.5  1.6 2.3  0.6 2.8  0.3 3  0.3 3.1  0.7 3  0.8 1.18  0.2 1.38  0.3 † 1.26  0.3
Internal 2.1  2 3.1  2.3 1.6  1.2 2.2  0.8 1.4  0.2 1.5  0.2 1.5  0.4 1.7  1 1.16  0.2 1.37  0.3 † 1.21  0.3
Thalamus 1.55  0.2 1.8  0.4 †0.087 1.67  0.2
ACC Ventral 0.81  0.3 0.9  0.4 0.91  0.3 1.36  0.4 1.64  0.6 1.44  0.3 1.39  0.3
Dorsal 0.58  0.2 0.7  0.2 0.67  0.1 1.84  0.5 2.21  0.6 1.99  0.4 1.88  0.3
Frontal
cortex
Dorsolateral 0.38  0.2 0.44  0.3 0.41  0.1 1.23  0.4 1.49  0.4 1.37  0.4 1.21  0.4
Medial 0.41  0.2 0.49  0.3 0.45  0.2 1.51  0.4 1.78  0.5 1.63  0.4 1.50  0.5
Orbital 0.51  0.3 0.62  0.3 0.54  0.2 1.13  0.3 1.34  0.3*0.053 1.27  0.2 1.10  0.3*‡†‡0.066
Ventral 0.37  0.2 0.45  0.3 0.39  0.1 1.06  0.3 1.18  0.3 1.18  0.2 1.00  0.3
Limbic
structures
Amygdala 0.96  0.3 0.9  0.3 0.91  0.3 1.19  0.2 1.24  0.2 1.26  0.1 1.10  0.2
Hippocampus 0.61  0.2 0.63  0.2 0.6  0.2 1.44  0.3 1.46  0.2 1.44  0.3 1.34  0.3
Insula 1.05  0.2 1.17  0.3 1.09  0.2 1.52  0.4 1.67  0.4 1.62  0.3 1.46  0.3
Raphe 1.8  0.2 2.17  0.4 2.18  0.2 0.56  0.2 0.58  0.1 0.52  0.1 0.47  0.3
Data represent mean Ki or BPND values  SD. Symbols in italics indicate significant differences. p 	 0.05 between states: *baseline versus early symptomatic;
†baseline versus full symptomatic; ‡baseline versus; *†early versus full
symptomatic; *‡early symptomatic versus recovered; and †‡full symptomatic versus recovered.
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Regression analyses showed that [18F]DOPA uptake col-
lected during the full symptomatic state in the anterior ventral
striatum was inversely correlated with the motor status of the
monkeys (r  0.79, p  0.03, n  7, data not shown).
Negative correlations were also detected between Ki values in
the full symptomatic state and recovery time in the anterior
ventral striatum and the GPe (respectively r  0.91, p 
0.005 and r  0.83, p  0.022, n  7; Fig. 3E). In addition, we
found negative relationships between [11C]DASB BPND col-
lected during the symptomatic state in the posterior putamen
and the motor score (r  0.90, p  0.036, n  5) and
recovery time (r  0.88, p  0.046, n  5). There was also a
negative correlation between [11C]DASB bindingcollected in
the symptomatic state and the recovery time in the GPe (r 
0.89, p  0.043, n  5; Fig. 6C). Finally, there was a positive
relationship between the percentage of cell death in A8 and the
amount of [11C]raclopride binding in the symptomatic state
compared with baseline within the anterior ventral striatum
(r  0.92, p  0.03, n  5). The monkeys with greater neuro-
nal loss in the retrorubral area were those with the larger
Figure 2. PET imaging at baseline. A, Spatially normalized mean parametric images of each radiotracer collected at baseline superimposed on the brain Macaca fascicularis MRI template
(Ballanger et al., 2013). The parametric images are shown in color, whereas the MRIs are shown in grayscale. Colors represent the level of binding expressed as uptake ratio using the cerebellum as
a nonspecific reference for each radioligand (Ki for [
18F]DOPA and BPND for [
11C]raclopride, [11C]DASB, and [18F]MPPF). Red represents high Ki or BPND, whereas blue denotes low Ki or BPND. For each
radiotracer, three coronal (first three rows), one sagittal (fourth row), and one transaxial (fifth row) slices are shown. B, Negative correlation reported within the pallidum internal (GPi) and external
(GPe) parts between both the [11C]Raclopride and [11C]DASB BPND collected at baseline and the maximal parkinsonian score obtained in the full symptomatic state (n  5).
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increase in [11C]raclopride binding in the symptomatic state
compared with baseline within this specific region. In parallel,
we found a negative relationship between the percentage of
cell death in A10 and the difference in [11C]DASB binding
between the full symptomatic state and baseline in the caudate
nucleus in its anterior (r  0.97, p  0.03) and posterior (r 
0.99, p  0.006) parts (n  4). The monkeys with less neu-
ronal loss in the ventral tegmental region were those with the
larger increase in [11C]DASB binding in the symptomatic state
compared with baseline within this structure.
Figure 3. [ 18F]DOPA uptake modifications. A, ROI assessment of [18F]DOPA uptake (Ki) between the different states (n: number of animals in each state). Asterisks indicate significant differences
( p 	 0.05). The bar graphs show the mean  SD. B, C, SPM showing changes in [18F]DOPA uptake (Ki) rendered over coronal (first row), sagittal (second row), and transaxial (third row) sections
of the brain Macaca fascicularis MRI template from Ballanger et al. (2013). The statistical threshold of the voxel-based analyses was set at p 	 0.001 uncorrected. Color bars represent the t value.
Specifically, B displays the significant cluster of increase Ki observed within the left anterior putamen in the early symptomatic state compared with baseline and C displays significant clusters
(involving the bilateral putamen) of decreased Ki observed in the recovered state compared with baseline. D, E, Correlation analyses between [
18F]DOPA uptake (Ki) and motor score or recovery time
during the different states. In particular, motor scores were negatively correlated with Ki values within the external pallidum (GPe) collected in the early symptomatic state (D, n  4) and recovery
time was negatively correlated with Ki values within the GPe and the ventral striatum collected during the full symptomatic state (E, n  7). For illustration, results from voxelwise regression with
SPM are shown at a more liberal threshold (uncorrected p 	 0.05, D, and p 	 0.01, E). Color bars represent the t value.
Ballanger et al. • Imaging DA and 5-HT on MPTP Monkeys J. Neurosci., February 3, 2016 • 36(5):1577–1589 • 1583
Changes in the recovered state
Interestingly, ROI-based analysis showed no statistical difference
in [18F]DOPA uptake between the full symptomatic and recov-
ered states, whereas, compared with the early symptomatic state,
[18F]DOPA uptake was greatly decreased in the posterior stria-
tum (putamen (F(1,15)  13.28; p  0.012) and caudate (F(1,15) 
7.82; p  0.04). Compared with baseline, the loss of [18F]DOPA
uptake was observed in both the putamen in its anterior (F(1,15) 
Figure 4. [ 11C]Raclopride binding potential modifications. A, ROI assessment of [11C]raclopride binding potential (BPND) between the different states (n: number of animals in each state).
Asterisks indicate significant differences ( p 	 0.05). The bar graphs show the mean  SD. B–D, SPM showing changes in [11C]raclopride binding potential (BPND) rendered over coronal (first row),
sagittal (second row), and transaxial (third row) sections of the brain Macaca fascicularis MRI template from Ballanger et al. (2013). The statistical threshold of the voxel-based analyses was set at
p 	 0.001 uncorrected. Specifically, B and C display the significant clusters of increase BPND within the bilateral posterior putamen observed in both the early symptomatic (B) and full symptomatic
(C) states compared with baseline, whereas D displays the significant clusters of decreased BPND within the striatum and the limbic part of the ACC (BA 25) observed in the recovered state compared
with the full symptomatic condition. Color bars represent the t value.
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10.48; p  0.033) and posterior (F(1,15)  17.62; p  0.0047) parts
and the posterior caudate nucleus (F(1,15)  14.47; p  0.009),
with a trend in the anterior caudate (F(1,15)  8.52; p  0.053). In
parallel, ROI analysis of [11C]raclopride BPND did not reveal any
difference between the recovered state and baseline. However,
there was an overall tendency for decreased [11C]raclopride BPND
in the recovered state compared with the symptomatic state.
This decrease was significant in the anterior striatum caudate
(F(1,12)  14.38; p  0.015) and putamen (F(1,12)  14.20; p 
0.016) (Fig. 4A). In addition, SPM analysis confirmed the ROI
analysis by revealing two clusters within the right anterior puta-
men (k  249, T  9.22) and the right anterior caudate (k  80,
T  8.59), as well as a significant cluster of decreased [11C]raclo-
pride BPND within the limbic ACC (k  877, T  14.09; Fig. 4D).
Finally, assessment of the 5-HT system revealed a significant de-
crease of [18F]MPPF BPND in the orbitofrontal cortex (compared
with the early symptomatic state; F(1,15)  10.62; p  0.03) and a
trend for decreased [18F]MPPF BPND in the orbitofrontal cortex
and decreased [11C]DASB BPND in the posterior putamen (com-
pared with the full symptomatic state; F(1,15)  7.30; p  0.066
and F(1,7)  7.51; p  0.058, respectively).
Regression analyses showed that recovery time was inversely
related to the [18F]DOPA uptake collected in the recovered state
in the anterior ventral striatum (r  0.8; p  0.034, n  7, data
not shown), as well as to the [18F]MPPF binding collected in the
hippocampus during the recovered state (r  0.76, p  0.047,
n  7, data not shown) and the [11C]DASB binding (n  5) in
multiple regions: the hippocampus (r  0.99, p  0.004), the
amygdala (r  0.98, p  0.02), the GPe (r  0.99, p  0.007),
the GPi (r  0.99, p  0.001), the posterior parts of the puta-
men and ventral striatum (r  0.99, p  0.009 and r  0.96,
p  0.036, respectively), and the anterior caudate (r  0.96, p 
0.043). In parallel, a positive significant relationship between re-
covery time and [11C]raclopride binding in the posterior puta-
men collected in the recovered state was found (r  0.82, p 
0.048, n  7, data not shown). Finally, cell death in A9 was pos-
itively correlated with the delta of [18F]DOPA uptake between
baseline and recovered state within the GPe and the putamen
posterior, as well as the putamen posterior ventral (r  0.83, p 
0.04, r  0.81, p  0.049, and r  0.84, p  0.04 respectively, n 
6). The monkeys with greater neuronal loss in the SNc were those
with a larger decrease in [18F]DOPA uptake in the recovered state
compared with baseline within these three regions.
Discussion
To our knowledge, this is the first multitracer PET imaging study
in nonhuman primates investigating dopaminergic and seroto-
nergic changes both presynaptically and postsynaptically in four
different motor states. Two main results emerged. First, different
compensatory mechanisms were highlighted, depending on the
level of dopaminergic depletion. In particular, our findings sup-
ported the importance of dopaminergic neurotransmission in
extrastriatal structures (GPe and ACC) for compensation with
an early presynaptic regulation followed by more prominent
changes in the expression of D2/D3 dopaminergic receptors
during recovery. Second, we identified early changes in the
expression of 5-HT1A receptors and presynaptic serotonergic
modifications strongly related to the recovery time.
Different DA compensatory mechanisms depending on the
parkinsonian state
During the early symptomatic state, we found an increase in
[18F]DOPA uptake (thought to reflect increased AAAD activity)
in the anterior putamen, consistent with the classic hypothesis of
dopaminergic striatal compensation in the surviving fibers (Lee
et al., 2000; Pifl and Hornykiewicz, 2006). This was associated
Figure 5. [ 18F]MPPF binding potential modifications. A, ROI assessment of [18F]MPPF binding potential (BPND) between the different states (n: number of animals in each state). The bar graphs
show the mean  SD. B, SPM showing changes in [18F]MPPF BPND rendered over coronal (first row), sagittal (second row), and transaxial (third row) sections of the brain Macaca fascicularis MRI
template from Ballanger et al. (2013). The statistical threshold of the voxel-based analysis was set at p 	 0.001 uncorrected. Color bars represent the t value. B, Significant clusters of increased
[18F]MPPF BPND observed in the early symptomatic state compared with baseline within the anterior caudate and at the cortical level within the orbitofrontal cortex and the dorsal ACC.
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with an increase in [11C]raclopride binding (thought to reflect an
increased number of dopaminergic D2/D3 receptors) specifically
in the posterior striatum, similar to PD patients (Nandhagopal et
al., 2011). Because parkinsonian motor features mainly depend
on the degree of DA depletion in the sensorimotor striatum
(Kaasinen et al., 2000; Nandhagopal et al., 2009), it is not surpris-
ing that the few remaining fibers in this territory are also involved
in the early compensatory phenomenon. A strength of our pro-
gressive protocol was the possibility of collecting behavioral and
histological markers, which allowed us to perform correlation
analyses with the PET data to gain additional information. Such
analyses revealed the importance of the relationship between do-
paminergic level in the GPe and the appearance and severity of
the motor symptoms. In particular, the more the monkeys pre-
sented parkinsonian symptoms during the early symptomatic
state, the less [18F]DOPA uptake was observed in the GPe, sug-
gesting its implication in early compensatory mechanisms, prob-
ably by maintaining the minimum DA concentration required
for normal motor functioning. Interestingly, in de novo parkin-
sonian patients, an increase of [18F]DOPA uptake has been re-
ported in the GPi (Whone et al., 2003; Pavese et al., 2012). It is
notable that [18F]DOPA uptake has been shown to reflect the
activity of overall brain monoaminergic population. Accord-
ingly, we cannot exclude the possibility that an increase in
Figure 6. [ 11C]DASB binding potential modifications. A, ROI assessment within the basal ganglia (BG) of [11C]DASB binding potential (BPND) between the different states (n: number of animals
in each state). Asterisks indicate significant differences ( p 	 0.05). The bar graphs show the mean  SD. B, SPM showing changes in [11C]DASB BPND rendered over coronal (first row), sagittal
(second row), and transaxial (third row) sections of the brain Macaca fascicularis MRI template from Ballanger et al. (2013). The statistical threshold of the voxel-based analysis was set at p 	 0.001
uncorrected. Color bars represent the t value. Specifically, the figure illustrates the increase of [11C]DASB BPND observed in the full symptomatic state compared with baseline within the bilateral
posterior putamen. C, D, Correlation analyses between [11C]DASB BPND and recovery time during the full symptomatic and recovered states. Overall recovery time was negatively correlated with
[11C]DASB BPND within the posterior putamen and the external pallidum during the full symptomatic state (C, n  5) and within the pallidum, the posterior putamen and ventral striatum, the
anterior caudate, and the hippocampus and amygdala during the recovered state (D, n  4).
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[18F]DOPA uptake might also reflect the AAAD activity of sero-
tonergic terminals (Pavese et al., 2012). This issue needs further
study.
The recovered state is particularly interesting because this
probably represents the lesional situation closest to PD patients
around the time of diagnosis. Indeed, we showed an SNc cell loss
of 74%, a reduction of [18F]DOPA uptake by 63% in the
striatum of recovered monkeys that was higher in the posterior
putamen (72%), and a relative sparing of AAAD activity in the
anterior ventral striatum throughout the different states (Doudet
et al., 2006; Blesa et al., 2012). These findings are consistent with
the extensive loss of dopaminergic neurons that has already taken
place when patients are diagnosed with PD (Hornykiewicz and
Kish, 1987; Morrish et al., 1998); the characteristic caudorostral
gradient of DA degeneration and greater vulnerability of the do-
paminergic projection onto the posterior putamen region, as re-
ported in PD patients (Snow et al., 2000; De La Fuente-Fernández
et al., 2003); and the partial preservation of the mesolimbic DA
innervation also observed in PD patients (Farley et al., 1977;
Brooks and Piccini, 2006). Also of interest were the relationships
reported between dopaminergic activity within the posterior pu-
tamen (as revealed by PET), cell loss in the SNc, the maximal
motor impairment, and the recovery time. Indeed, recovered
monkeys with higher SNc cell loss were those with greater par-
kinsonian impairment and higher reduction of [18F]DOPA
uptake in the posterior putamen compared with baseline. More-
over, the monkeys with longer recovery were those with higher
[11C]raclopride binding, suggesting greater DA depletion in this
structure. Moreover, we provided further evidence that dopami-
nergic fibers remaining inside the associative limbic territory of
the striatum could also be involved in the recovery process (Mou-
nayar et al., 2007; Boulet et al., 2008). This was reflected within
the anterior ventral striatum with the negative correlation be-
tween recovery time and [18F]DOPA uptake collected in both the
symptomatic and recovered states. The monkeys with high
AAAD activity in the anterior ventral striatum had faster recov-
ery. Finally, in both the symptomatic and recovered states, striatal
AAAD activity was very low compared with baseline with no
significant difference between them, as observed previously
(Boulet et al., 2008; Blesa et al., 2012). This lack of difference
between these opposite motor states strongly suggests the exis-
tence of extrastriatal mechanisms during recovery. Indeed, we
demonstrated a significant decrease in the limbic ACC during
this period. Moreover, we found that monkeys with a higher level
of [18F]DOPA uptake in the GPe presented faster recovery, con-
firming the contribution of pallidal dopaminergic neurotrans-
mission also in the recovery mechanisms (Mounayar et al., 2007;
Neumane et al., 2012).
Serotonin modifications: implications for compensation or
indirect markers of competition with the DA system
Previously, we suggested a role for serotonergic neurotransmis-
sion in motor recovery by showing an increase of striatal seroto-
nergic fibers in recovered monkeys (Mounayar et al., 2007). Here,
we report an increase in [11C]DASB binding within the BG dur-
ing the symptomatic state, confirming and extending previous
results obtained with immunohistological (Mounayar et al.,
2007) and biochemical (Boulet et al., 2008) techniques. Specifi-
cally, the changes mainly involved the posterior putamen and the
GPe, in which negative correlations were reported between
[11C]DASB binding and recovery time. These results strongly
suggested a positive involvement of serotonergic innervation in
compensation within these structures, at least for functional mo-
tor recovery. However, we cannot exclude that this SERT upregu-
lation is not directly responsible for the recovery phenomenon,
but rather is an artifact related to the competition between the
5-HT and DA systems. A decrease in DA fibers may allow the
sprouting process of serotonergic fibers to take place, leading to
an increase in density of serotonergic terminals, as observed in
the present study with the [11C]DASB radiotracer. Nevertheless,
if the 5-HT system is not involved in the recovery process, how
can we explain the strong correlations observed in the recov-
ery state between [11C]DASB binding and recovery time in many
brain structures (including the BG, hippocampus, and amy-
gdala)? Consistent with this idea, we recently showed that admin-
istration of 3,4-methylenedioxy-N-methamphetamine to induce
a 5-HT lesion in MPTP-recovered monkeys led to the reappear-
ance of the rigidity only, showing the importance of 5-HT trans-
mission in the posterior putamen and the GPi for this particular
symptom (Beaudoin-Gobert et al., 2015).
At the postsynaptic level, the present study revealed early
changes in the expression of 5-HT1A receptors in subcortical and
cortical structures that were less affected by the MPTP-induced
dopaminergic degeneration, such as the anterior caudate, the
ACC, and the OFC. Although this does not provide direct evi-
dence for the involvement of 5-HT1A receptors in early compen-
satory mechanisms, it might be interesting to investigate in
humans whether [18F]MPPF could be a promising biomarker of
early degenerative changes in PD. This should be explored fur-
ther, because postmortem studies have found an increase in
5-HT1A receptor levels in both the orbitofrontal and temporal
cortex of parkinsonian patients (Chen et al., 1998; Huot et al.,
2012).
Finally, the inverse relationship observed in multiple regions
between the [11C]DASB binding collected at baseline and the
maximal motor impairment obtained in the full symptomatic
stage (or the total time for recovery) raises the question of
whether baseline density of serotonergic terminals will predict
the intensity of motor impairment after MPTP treatment. In-
deed, the monkeys with lower levels of [11C]DASB binding at
baseline had a higher maximal motor score in the parkinsonian
condition. Is it possible that the [11C]DASB radiotracer may be a
marker of vulnerability to develop symptom expression? In the
same vein, it has been suggested that alterations in availability of
serotonergic terminals may be an important factor in the devel-
opment of anxiety (Reimold et al., 2008; Oler et al., 2009). Ac-
cordingly, is there a relationship between the level of anxiety and
the vulnerability of some animals to express parkinsonian symp-
toms and their ability to recover from the parkinsonian state?
Further investigations should be performed to elucidate these
issues.
In conclusion, the present work highlights the role of pallidal
dopaminergic neurotransmission in both the early compensatory
mechanisms and the functional recovery mechanisms, with re-
duced AAAD activity closely related to the appearance or perse-
veration of motor symptoms. This finding expands possibilities
for new treatments (such as cell-based therapies) that could arti-
ficially promote dopaminergic levels within the GPe to delay dis-
ease expression. In parallel, this study provides preliminary
evidence of the role of the serotonergic system in compensatory
mechanisms. Nonetheless, future studies are needed to deter-
mine whether there are changes in SERT availability in the early
symptomatic state and if [18F]MPPF PET imaging might be a
promising biomarker of early degenerative changes in PD.
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Blesa J, Pifl C, Sánchez-González MA, Juri C, García-Cabezas MA, Adánez R,
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Thobois S, François C, Sgambato-Faure V, Tremblay L (2012) Effects of
dopamine and serotonin antagonist injections into the striatopallidal
complex of asymptomatic MPTP-treated monkeys. Neurobiol Dis 48:
27–39. CrossRef Medline
Oler JA, Fox AS, Shelton SE, Christian BT, Murali D, Oakes TR, Davidson RJ,
Kalin NH (2009) Serotonin transporter availability in the amygdala and
bed nucleus of the stria terminalis predicts anxious temperament and
brain glucose metabolic activity. J Neurosci 29:9961–9966. CrossRef
Medline
Pavese N, Simpson BS, Metta V, Ramlackhansingh A, Chaudhuri KR,
Brooks DJ (2012) [18F]FDOPA uptake in the raphe nuclei complex
reflects serotonin transporter availability: a combined [18F]FDOPA
and [11C]DASB PET study in Parkinson’s disease Neuroimage 59:
1080 –1084. CrossRef Medline
Pessiglione M, Guehl D, Hirsch EC, Féger J, Tremblay L (2004) Disruption
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